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Neil was 4 years old when he was diagnosed
with acute lymphoblastic leukemia, and
7 years old when he completed his treatment. For Neil, there was little he remembered of life at any time other than
as a patient with cancer. On the day of his
last planned treatment, as with many such
visits, we walked into his room with a
certificate of completion, a gift bag, and
a cheerful song. Much to our surprise,
Neil sat quietly in his chair and stared at
the corner of the room. We halted our
song midsentence and Neil looked at us
and asked, “Is it okay if I don’t feel like
celebrating?” We, the members of the
clinic team, were left feeling abashed,
wondering how we could have so misconceived the situation and how often
we may have committed the same error
in the past.
Neil’s reaction taught us much about
the potential differences in perceptions
between patients, families, and health care
team members around the completion of
planned upfront therapy, and guided us
to take a look at how we approached the
occasion. We realized that what patients
and families really need at this important
moment is an opportunity to discuss their
fears and hopes and to have their questions
answered; as much as on the day they first
faced the diagnosis of cancer, they need a
conversation.
So much of oncology care occurs in
conversations. Not more than a decade ago,
the article by Mack and Grier1 in Journal of
Clinical Oncology offered a practical and
concise approach to delivering the bad
news of a cancer diagnosis and supporting
families during such a tumultuous time.
This early conversation is of paramount

importance in preparing patients and
families for their cancer journey and for
establishing a therapeutic relationship.
It influences much of their upcoming experiences and is often remembered for
years to come.
At the other end of the cancer treatment
journey is another important conversation
but one that receives less structured attention in our mental scripts or in our training
programs: the completion of therapy talk,
an important conversation in its own right
and with its own requirements for individualized structure and content. Our
personal approach to this conversation,
culled from years of trial and error and
encapsulated in three main goals, is presented here. Many of the concepts discussed
below are not unique to pediatrics but are
relevant to all survivors who reach this
significant milestone.
Perspectives
The first goal is to identify the patients’ and
families’ perspective of this important moment, without setting expectations. We now
begin the conversation by simply asking,
“How do you feel today?” and allowing
families to express their emotions, positive
or negative. For most families, it is often a
moment of mixed emotions, a complicated
amalgam of apprehension, uncertainty,
relief, and hope.
Families may express the fear that
completion of active therapy today may not
mean the same thing as end of therapy for
good. Indeed, we know that for a proportion
ofpatients, subsequentexperience of relapse
will unfortunately occur, and the families’
worst fears will be realized. It is of utmost
importance to acknowledge these fears and
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to place them in the proper context for each patient’s
circumstance.
Other families may be concerned that ceremony of any sort
will build resentment or increase shock if relapse occurs. We try
to give families permission to celebrate, to mark the end of a
long journey, and, indeed, to try to think of the occasion as good
news. We still have the gifts and certificates prepared, but we
leave them aside for the latter part of the conversation and bring
them in only if appropriate.
We also take this opportunity to emphasize that families
are not losing their care team. We recognize that the clinic and
hospital ward has become somewhat of a second home and
that completing therapy feels, for some, like they are losing that
home. We explain that the same team will continue to observe
them for a long time, and although these families may be in the
clinic less often, we will always be there for them when they
need us.
Moving to a New Normal
During active treatment, a plan is available for every detail and
is displayed in tangible schedules and roadmaps. Families may
fear that the completion of therapy phase will bring about a
loss of the structure and routine that they found comforting
during active treatment. We usually address four key actions
that patients can expect when treatment ends, including
removal of their central line, stopping Pneumocystis jirovecii
pneumonia prophylaxis, resumption of regular immunizations, and change in the management plan for fevers. These
four milestones can serve as valuable teaching moments
for families and as opportunities to discuss the risk of
relapse, the recovery of the immune system, and healthy
lifestyle choices.
Changes in a family’s and child’s routines are an essential
step forward in rebuilding normalcy. What this new normal
looks like will be different for each patient, depending on the
lasting impact the cancer has had on their physical or psychosocial health.2 Ideally, a smooth transition occurs when
efforts are made to maintain normal routines and relationships throughout active treatment.
We emphasize re-establishing a therapeutic relationship
with their pediatrician and reconnecting with friends and
classmates. Whenever possible, we also encourage a family
vacation, a well-deserved respite from months or years of
rigorous therapy, and offer financial support from local
charities, such as the Children’s Wish Foundation. We inform parents and children that physical and psychological
770

recovery is a work in progress that takes a long time and
does not happen as soon as therapy ends. We also address the
possible long-lasting psychological impact of cancer and
discuss letting the child find a balance between a return to
their old world and the preservation of pieces of their new
identity as a survivor of cancer.
Ongoing Monitoring
The third goal is to outline a schedule of off-therapy monitoring, usually composed of radiologic scans, blood tests, and
clinic visits. As with active therapy, we find it helpful to provide
families with a roadmap that includes the surveillance schedule,
making sure to explain the rationale for each item. Even if earlier
detection of relapse offers no specific advantage to the patient,
most families have told us that they would not be comfortable
without some form of surveillance.
Some families ask directly about the risk of the cancer
coming back and worry that coming off therapy means that the
cancer is more likely to come back. We address these concerns
by showing them survival curves that help us convey the
important message that coming off active treatment does not
increase the child’s probability of experiencing recurrence
and that this risk decreases with time.
A family may experience the conversation about the late
effects of cancer therapy as another bringing bad news.
Families may feel like they are hearing about these things for
the first time, although they were often introduced to the
idea of late effects with the initial disclosure.3 During the day
one talk, discussion about late effects seemed like a remote
concern or a small price to pay for the chance of cure. At the
completion of therapy talk, discussion about late effects
increases in its relevance and is an opportune moment to
shift focus from cancer care to survivorship care. It is vitally
important to talk about the risks of late effects directly with
the child and to do this an age-appropriate way. Adolescents,
in particular, need to be empowered to take increasing
ownership of their health information. Active patient engagement in survivorship care promotes early recognition of
late effects and works to strengthen the therapeutic relationship
with the care team.
Final Thoughts
Completion of active therapy is a momentous occasion. It is a
time to explore what patients and families feel about how far
they have come and to discuss their hopes and fears for the
future. It is an opportunity to inform them that they will
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continue to be supported in both the triumphs and challenges that may follow. Just as the initial investment of time,
planning, and compassionate communication on day one
affected adjustment to the cancer diagnosis, so will our investment in the conversation here affect adjustment to the
process of recovery. And just as with the day-one talk, this
conversation typically happens in installments over many
days, weeks, and, often, months. The day one talk and the
completion of therapy talk are the two shores of the cancer
treatment journey. As their oncologists, we recognize the
importance of compassionate communication to provide not
only information but to convey our support and dedication to
our patients, not just while they receive therapy but long after
they are done.
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